Physician profile
Vincent Lewis
NPI 1275791147
$7,776.62
in general payments reported to CMS, 2019-2025
35 companies · $1,317 in 2025
The $1,317 reported for 2025 was more than what 85% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,631 · 2022: $1,860 · 2023: $1,488 · 2024: $1,481 · 2025: $1,317.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,244 · Education: $41.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,244.27 |
| Education | $41.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $967.17 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $593.21 | 2021-2025 | |
| Abbvie INC. | $535.28 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $533.19 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $484.89 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novartis Pharmaceuticals Corporation | $471.70 | 2021-2025 | |
| Novo Nordisk INC | $470.32 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $460.28 | 2021-2025 | Repatha, Otezla, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $380.97 | 2021-2024 | Jardiance, Tradjenta, Stiolto Respimat |
| Takeda Pharmaceuticals U.S.A., INC. | $233.51 | 2021-2023 | Trintellix |
| Exact Sciences Corporation | $227.75 | 2023-2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $217.66 | 2021-2022 | |
| Axsome Therapeutics, INC. | $188.08 | 2022-2025 | Auvelity |
| Kowa Pharmaceuticals America, INC. | $167.42 | 2021-2023 | Livalo, Seglentis |
| Merck Sharp & Dohme LLC | $164.97 | 2021-2024 | Belsomra, Steglatro, Gardasil 9 |
Show all 35 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vincent Lewis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.